In a patient about to start bortezomib‑lenalidomide‑dexamethasone therapy for multiple myeloma with TSH 6.5 mIU/L and normal free T4, should levothyroxine be initiated now?

Treatment Recommendation for Subclinical Hypothyroidism Before Starting VRd

Do not initiate levothyroxine at this time; instead, recheck TSH in 4-6 weeks after starting bortezomib-lenalidomide-dexamethasone therapy, as dexamethasone may normalize thyroid function.

Rationale

Your patient has subclinical hypothyroidism (TSH 6.53 mIU/L with normal free T4). The key consideration here is that dexamethasone, a core component of the VRd regimen, can suppress TSH levels through its glucocorticoid effects on the hypothalamic-pituitary-thyroid axis 1.

Why Waiting is Appropriate

• TSH is below the treatment threshold: With TSH between 4.5-10 mIU/L, guidelines explicitly state that routine levothyroxine treatment is not recommended 2. The evidence does not support clear benefits for early therapy in this range, and the likelihood of symptomatic improvement is small.

• Dexamethasone effect: Glucocorticoids like dexamethasone can lower TSH levels 1. Starting levothyroxine now may lead to overtreatment once the myeloma regimen begins, potentially causing subclinical hyperthyroidism (which occurs in 14-21% of treated patients) 2.

• No urgent indication: The patient has normal T4, meaning tissue thyroid hormone levels are adequate. There is no evidence that delaying treatment by 4-6 weeks in this scenario affects morbidity or mortality 2.

Clinical Algorithm

1. Document baseline thyroid function (already done: TSH 6.53, normal T4)

2. Start VRd therapy as planned without levothyroxine

3. Recheck TSH and free T4 in 4-6 weeks after initiating chemotherapy:

   • If TSH normalizes or decreases: Continue monitoring every 6-12 months
   • If TSH remains >10 mIU/L: Consider starting levothyroxine at 25-50 mcg daily 3
   • If TSH remains 6-10 mIU/L with symptoms: Consider trial of levothyroxine only if clear hypothyroid symptoms present 2

4. Monitor for symptom development: If clear hypothyroid symptoms emerge (fatigue beyond what's expected from myeloma/chemotherapy, cold intolerance, constipation), recheck thyroid function earlier

Important Caveats

• If TSH were >10 mIU/L: Treatment would be reasonable even before starting chemotherapy, as progression risk increases and potential benefits are more compelling 2

• Avoid overtreatment: Starting levothyroxine unnecessarily risks cardiac complications (arrhythmias, angina) particularly relevant given potential cardiotoxicity from myeloma therapy 3

• Drug interactions: If levothyroxine is eventually needed, ensure it's taken 30-60 minutes before breakfast on an empty stomach, separated from other medications 1

The conservative approach of waiting 4-6 weeks allows you to assess the net effect of dexamethasone on thyroid function before committing to long-term thyroid hormone replacement, avoiding the risks of overtreatment while not compromising outcomes in this subclinical range.